Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma
Acta Haematologica · 2024
DOI: 10.1159/000539066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, 2024. Verfasst von Taku Kikuchi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Monoclonal, Humanized, Cytomegalovirus, Cytomegalovirus Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Introduction
Some treatments are associated with cytomegalovirus (CMV) reactivation (CMVRA) in patients with multiple myeloma (MM). However, no reports exist on the association between elotuzumab and CMVRA. Therefore, we assessed the incidence of CMVRA in patients with MM who received elotuzumab therapy.
Methods
The medical records of 85 patients who underwent elotuzumab therapy were included in the retrospective analysis for CMV positivity.
Results
Thirty patients were tested for CMV antigenemia during elotuzumab therapy, and 16 were positive for CMV antigenemia; the cumulative incidence rate of CMVRA 6 months after elotuzumab initiation was 18.4%. The history of allogeneic stem cell transplantation (allo-HSCT) was significantly more common in the CMVRA group (31.2%) than that of the group without CMVRA (8.7%). However, even among patients who did not undergo allo-HSCT, the cumulative incidence rate of CMVRA at 6 months was 15.1%. During CMVRA, the symptoms included fever in 8 cases, while retinitis was observed in 1 case. Five patients required antiviral therapy and CMV antigenemia resolved in all but 1 case.
Conclusion
Although the patient population was heterogeneous, CMVRA cannot be underestimated during elotuzumab therapy, and evaluation of CMVRA, especially in symptomatic cases, is clinically important.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Zitieren
APA
Kikuchi, T., Tsukada, N., Kunisada, K., Nomura-Yogo, M., Oda, Y., Sato, K., Takei, T., Ogura, M., Abe, Y., Suzuki, K., & Ishida, T. (2024). Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma. Acta Haematologica. https://doi.org/10.1159/000539066
Vancouver
Kikuchi T, Tsukada N, Kunisada K, Nomura-Yogo M, Oda Y, Sato K, et al. Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma. Acta Haematologica. 2024. doi:10.1159/000539066
BibTeX
@article{Kikuchi2024,
author = {Kikuchi, Taku and Tsukada, Nobuhiro and Kunisada, Kodai and Nomura-Yogo, Moe and Oda, Yuki and Sato, Kota and Takei, Tomomi and Ogura, Mizuki and Abe, Yu and Suzuki, Kenshi and Ishida, Tadao},
title = {Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma},
journal = {Acta Haematologica},
year = {2024},
doi = {10.1159/000539066}
}
EUVIMED